Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
NCT ID: NCT01710202
Last Updated: 2015-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2012-10-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
NCT02900092
Pharmacogenetics of Antidepressant-Induced Disinhibition
NCT03953014
Examination of Brain Serotonin Receptors in Patients With Mood Disorders
NCT00026832
Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury
NCT00208585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
No interventions assigned to this group
Experimental: Hydrocortisone
Group will receive 20mg oral hydrocortisone
Hydrocortisone
Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydrocortisone
Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have you ever had an allergic reaction to hydrocortisone?
* Do you have diabetes or high blood pressure?
* Do you have any thyroid, liver, heart, lung, or kidney problems?
* Do you have herpes, HIV or any sexual transmitted disease?
* Are you currently pregnant or think you might be pregnant? Have you taken RU486, Plan B or "Morning After Pill" within the last 2 weeks? - Are you currently breastfeeding?
* Have you been sick within the last week? Do you have any fungal infections?
* Have you been exposed to measles or chicken pox in the last week?
* Have you ever had a seizure?
* Do you have any disease of bony tissue, such as osteoporosis?
* Do you have any autoimmune diseases, such as myasthenia gravis?
* Do you have multiple sclerosis?
* Do you have any condition that compromises you immune system function or causes you to be more likely to get sick?
* Have you had any recent surgeries?
* Do you have and gastrointestinal problems, such as ulcers, diverticulitis, colitis, hepatitis, or Crohn disease?
* Are you taking any of the following medications: nevirapine, telbivudine, sipuleucel-T (IV), natalizumab (IV)?
* Have you received any vaccinations within the last week?
* With the exception of vitamins, have you taken any medications in the last 3 days, including all over-the counter medications and/or supplements (e,g. Tylenol, ibuprofen, St. John's Wort, cold remedies)?
* Do you currently have or have you had in the past of any kind of cancer?
* Do you have any significant medical or psychiatric illnesses not listed above?
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert A Josephs, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Austin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas at Austin Department of Psychology
Austin, Texas, United States
University of Texas at Austin
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Josephs RA, Telch MJ, Hixon JG, Evans JJ, Lee H, Knopik VS, McGeary JE, Hariri AR, Beevers CG. Genetic and hormonal sensitivity to threat: testing a serotonin transporter genotype x testosterone interaction. Psychoneuroendocrinology. 2012 Jun;37(6):752-61. doi: 10.1016/j.psyneuen.2011.09.006. Epub 2011 Oct 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-12-0017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.